89
Reviewed transactions
62
With price data
4.5x
Median EV or valuation / revenue
17.2x
Median EV or valuation / EBITDA
| Year | Transactions | Priced | Median EV or valuation / revenue | Median EV or valuation / EBITDA |
|---|---|---|---|---|
| 2024 | 4 | 4 | 3.3x | 15.0x |
| 2023 | 14 | 12 | 4.1x | 21.6x |
| 2022 | 16 | 6 | 4.9x | 20.4x |
| 2021 | 18 | 14 | 4.7x | 14.9x |
| 2020 | 9 | 5 | 4.2x | 14.7x |
| 2019 | 6 | 5 | 4.4x | 18.7x |
| 2018 | 4 | 4 | 4.5x | 21.2x |
| 2017 | 10 | 7 | 4.7x | 17.7x |
Sortable transaction comps
Consumer transaction table
Rows with reported value
19 / 25
Acquisition value, USD
USD 22B
Investment capital, USD
-
Median EV or valuation / revenue
4.5x
Select up to 12 rows across filters and pages, then share or export the set.
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
25 shown of 89 matching transactions. Click any transaction row for more detail.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| GW Pharmaceuticals Control | 2021-02-03 | Jazz Pharmaceuticals | USD 7.2B | 7,200 | - | 12.9x | - | Confirmed 1 source | ||
| Microbiome Labs Control | 2021-01-06 | Novozymes | USD 125M Consideration | 125 | 3.1x | 6.0x | United States | Confirmed 1 source | ||
| Zicam Control | 2020-12-01 | Church & Dwight | USD 530M Consideration | 530 | 5.9x | 14.7x | United States | Confirmed 1 source | ||
| Smarty Pants Control | 2020-11-25 | Unilever | Undisclosed | Undisclosed | 4.0x | - | - | Confirmed 1 source | ||
| Valagro Control (10%) | 2020-10-06 | Syngenta Group | Undisclosed Undisclosed | Undisclosed | 3.4x | 17.5x | Global | Confirmed 1 source | ||
| Care/of Control | 2020-08-31 | Bayer | USD 225M | 225 | - | - | United States | Confirmed 1 source | ||
| Cremo Control | 2020-08-04 | Edgewell Personal Care | USD 235M Consideration | 235 | 4.1x | - | US | Confirmed 1 source | ||
| Thayers Natural Remedies Control | 2020-06-18 | L'Oréal | USD 400M Rumored Value | 400 | 7.3x | 13.3x | - | Estimated 1 source | ||
| Vital Proteins Control | 2020-06-10 | Nestlé Health Science | Undisclosed | Undisclosed | 4.3x | - | - | Confirmed 1 source | ||
| 2020-02-01 | ADM | Undisclosed | Undisclosed | - | - | Brazil | Unknown 1 source | |||
| Dermira Control | 2020-01-10 | Eli Lilly | USD 1 | 0 | - | - | - | Confirmed 1 source | ||
| Dr. Jart+ Control (33%) | 2019-11-18 | The Estée Lauder Companies | USD 1.9B | 1,902 | 3.8x | - | South Korea | Estimated 1 source | ||
| Quest Nutrition Control | 2019-08-22 | The Simply Good Foods Company | USD 1.0B Consideration | 1,000 | 2.9x | 17.4x | United States | Estimated 1 source | ||
| Filorga Control | 2019-07-11 | Colgate-Palmolive | EUR 1.5B Equity Purchase Price | 1,690 | 8.3x | - | France | Confirmed 4 sources | ||
| Tatcha Control | 2019-06-10 | Unilever | USD 500M Rumored Value | 500 | 5.0x | - | - | Estimated 1 source | ||
| Ranir Global Holdings LLC Control | 2019-05-09 | Perrigo | USD 750M Consideration | 750 | 2.6x | - | Grand Rapids, Michigan, United States | Estimated 1 source | ||
| OLLY Nutrition Control | 2019-04-18 | Unilever | Undisclosed Undisclosed | Undisclosed | 5.0x | 20.0x | United States | Confirmed 1 source | ||
| Ci:z Holdings Co., Ltd. Control | 2018-10-23 | Johnson & Johnson | USD 2.1B | 2,100 | 4.5x | 22.0x | Japan | Confirmed 1 source | ||
| First Aid Beauty Control | 2018-07-17 | P&G | USD 250M Rumored Value | 250 | 4.5x | - | US | Estimated 1 source | ||
| Probiotics International Control | 2018-07-02 | ADM | USD 243M Consideration | 243 | 5.6x | 21.2x | - | Estimated 1 source | ||
| Nutranext Control | 2018-03-12 | Clorox | USD 700M Consideration | 700 | 3.5x | 14.0x | - | Estimated 1 source | ||
| Sucampo Pharmaceuticals, Inc. Control | 2017-12-26 | Mallinckrodt | USD 1.2B | 1,200 | 4.6x | - | - | Confirmed 1 source | ||
| PCA Skin and EltaMD Control | 2017-12-18 | Colgate-Palmolive | USD 730M | 730 | 7.3x | - | - | Estimated 1 source | ||
| Atrium Innovations Control | 2017-12-05 | Nestlé | USD 2.3B Consideration | 2,300 | 3.3x | 19.0x | - | Confirmed 1 source | ||
| Ganeden Control | 2017-10-11 | Kerry Group | Undisclosed | Undisclosed | 6.0x | 20.0x | - | Confirmed 1 source |
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.